Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2015-06-17 02:07 |
Nombre d'actions et droits de vote au 16 juin 2015
|
French | 67.9 KB | ||
| 2015-05-19 08:30 |
IPH_number_of_shares_as_at_may_18_2015
|
English | 30.0 KB | ||
| 2015-05-19 08:30 |
Nombre d'actions et droits de vote au 18 mai 2015
|
French | 29.6 KB | ||
| 2015-05-05 08:31 |
INFORMATION FINANCIÈRE DU PREMIER TRIMESTRE 2015
|
French | 149.0 KB | ||
| 2015-05-05 08:31 |
Financial update for the first quarter of 2015
|
English | 142.7 KB | ||
| 2015-04-28 08:31 |
résultats AGM IPH
|
French | 32.6 KB | ||
| 2015-04-28 08:31 |
IPH AGM Outcome
|
English | 32.4 KB | ||
| 2015-04-24 08:01 |
Innate Pharma and AstraZeneca announce global agreement
|
English | 38.7 KB | ||
| 2015-04-24 08:01 |
Innate Pharma et AstraZeneca annoncent un accord global
|
French | 39.7 KB | ||
| 2015-04-16 08:30 |
IPH Sanofi Collaboration ADC
|
French | 72.9 KB | ||
| 2015-03-26 07:30 |
DSMB RECOMMENDS CONTINUATION OF EFFIKIR TRIAL WITH TWO ARMS
|
English | 35.9 KB | ||
| 2015-03-26 07:30 |
Poursuite de l'essai EffiKIR avec deux bras selon recommandation DSMB
|
French | 77.2 KB | ||
| 2015-03-23 07:30 |
AGM invitation and Reference document
|
English | 76.5 KB | ||
| 2015-03-23 07:30 |
Invitation AG et mise à disposition DDR
|
French | 76.5 KB | ||
| 2015-03-23 07:30 |
CP éligibilié PMA-PME
|
French | 69.3 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
